Celldex Therapeutics (TCE1) Stock Overview
A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TCE1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.93 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCE1 | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 18.1% | -0.9% | 1.8% |
| 1Y | n/a | 36.8% | 17.0% |
Return vs Industry: Insufficient data to determine how TCE1 performed against the Swiss Biotechs industry.
Return vs Market: Insufficient data to determine how TCE1 performed against the Swiss Market.
Price Volatility
| TCE1 volatility | |
|---|---|
| TCE1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: TCE1's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine TCE1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 198 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
Celldex Therapeutics, Inc. Fundamentals Summary
| TCE1 fundamental statistics | |
|---|---|
| Market cap | CHF 2.10b |
| Earnings (TTM) | -CHF 230.55m |
| Revenue (TTM) | CHF 703.07k |
Is TCE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCE1 income statement (TTM) | |
|---|---|
| Revenue | US$865.00k |
| Cost of Revenue | US$265.46m |
| Gross Profit | -US$264.60m |
| Other Expenses | US$19.05m |
| Earnings | -US$283.65m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.61 |
| Gross Margin | -30,589.13% |
| Net Profit Margin | -32,791.45% |
| Debt/Equity Ratio | 0% |
How did TCE1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/24 12:05 |
| End of Day Share Price | 2026/06/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celldex Therapeutics, Inc. is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Edward Nash | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |